Trial Profile

Phase Ib/II Study of Toripalimab In Combination With Rituximab Followed by R-CHOP Regimen (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone) for Elderly Naïve Patients With Diffuse Large B-cell Lymphoma

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 27 Jul 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Toripalimab (Primary) ; Cyclophosphamide; Doxorubicin; Prednisone; Rituximab; Vincristine
Indications Diffuse large B cell lymphoma; Follicular lymphoma
Focus Adverse reactions; Therapeutic Use
Acronyms TREND

15 Jun 2023 Results (n=48) of analysis of the Phase II Trend Trial presented at the 28th Congress of the European Haematology Association
13 Dec 2022 Results presented at the 64th American Society of Hematology Annual Meeting and Exposition.
06 Apr 2022 Planned primary completion date changed from 30 Dec 2022 to 30 Dec 2023.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com